The 24th CCM/E Oversight Committee Meeting was held with PR and SRs to review GC7 Period 2 (October–December 2024) Grant Performance and Key Challenges in Addis Ababa on March 13, 2025
The 24th CCM/E Oversight Committee Regular Meeting took place at Ellily International Hotel, bringing together Oversight Committee (OC) members, Principal Recipient (PR), Sub-Recipients (SRs), including Federal agencies. The meeting aimed to evaluate the programmatic and financial performance of Period 2 (October–December 2024) of the Global Fund GC7 Grant, identifying key challenges, and setting actionable recommendations with clear timelines.
Meeting Objectives and Key Discussions
The meeting was chaired by Ms. Boonto Krittayawan, Oversight Committee Vice Chair; the meeting aimed to:
- Review the performance of GC7 Period 2 across HIV, TB, Malaria, RSSH, and C19RM grants.
- Identify major bottlenecks impacting grant implementation.
- Discuss procurement, financial management, and supply chain issues.
- Develop concrete recommendations and action points with deadlines to improve execution and sustainability.
Mr. Abayneh Admas, the CCM/E Oversight and Compliance Officer, presented an overview of the GC7 period 2 performance, highlighting key findings on HIV, TB, Malaria, RSSH, and C19RM grants. Following this, Dr. Degefa Uma, the EPSS representative, provided an update on the procurement status of pharmaceuticals and health products and supply availability, .
A key part of the meeting was the in-depth discussions between the Oversight Committee, CCM/E Secretariat, and all Grant Coordinators, program leaders and SRs representatives. These discussions provided a platform to address performance gaps, financial execution challenges, and programmatic roadblocks.
Summary of Key Issues Discussed for Grant Performance Review (Period 2 of GC7 Grant Implementation)
- Low budget absorption rates for all GC7 grants Identification of delays in implementation and fund disbursement bottlenecks.
- Below the minimum stock level of essential Medicines for HIV, TB, and Malaria and diagnostics.
- Challenges related to delayed procurement processes and ERP system inefficiencies.
- Challenges in the distribution and accessibility of condoms
- Improve data quality problem and program efficiency
- Delays in budget transfers to CSOs, impacting delivery service timelines.
- Challenges in MOU signing between PRs and CSOs, delaying implementation.
- Need for better coordination among PRs, SRs, and implementing entities.
- Barriers to community-led monitoring (CLM) framework development.
